How Much Does Evenity (Romosozumab) Cost in New Jersey in 2026?

New Jersey Retail Pricing for Evenity in 2026

The average cash-pay price across New Jersey retail pharmacies in 2026 is $1,825 per monthly dose, matching the Amgen/UCB wholesale acquisition cost (WAC). This price applies to a single prefilled syringe kit containing two 105 mg/1.17 mL syringes administered as a 210 mg total dose.

Pricing varies minimally across NJ pharmacies for brand-name Evenity because no generic or biosimilar version exists as of mid-2026. The FDA-approved labeling specifies a fixed 210 mg monthly dose for all patients regardless of weight, which simplifies cost forecasting. Over the standard 12-month treatment window, uninsured patients face a total outlay near $21,900.

Specialty pharmacies in northern New Jersey (Bergen, Essex, Hudson counties) and southern corridors (Camden, Burlington) stock Evenity routinely. Most patients receive injections at their prescriber's office or an infusion center rather than self-administering at home, which can shift the billing pathway from pharmacy benefit to medical benefit depending on the plan.

New Jersey Medicaid Coverage

New Jersey Medicaid (NJ FamilyCare) covers Evenity with prior authorization for patients diagnosed with severe osteoporosis. The PA requirements align with the FDA indication: postmenopausal women at high risk for fracture, defined as a history of osteoporotic fracture or multiple risk factors, or patients who have failed or are intolerant to other osteoporosis therapies [1].

To secure approval, prescribers must document a T-score of -2.5 or below at the hip or spine on dual-energy X-ray absorptiometry (DXA), or a prior fragility fracture. The NJ Medicaid formulary committee updated its criteria in late 2024 to reflect the Endocrine Society's 2020 guideline recommendations for anabolic-first therapy in very high-risk patients. Approval turnaround typically runs 5 to 10 business days. Denials can be appealed through the NJ Division of Medical Assistance and Health Services within 20 calendar days.

Patients enrolled in NJ FamilyCare managed care organizations (Aetna Better Health, Amerigroup, Horizon NJ Health, Molina, UnitedHealthcare Community Plan, WellCare) should note that each MCO maintains its own PA form and turnaround timeline, though all must cover Evenity once PA criteria are met per state mandate.

Commercial Insurance Coverage in New Jersey

Most commercial plans available through the NJ marketplace and employer-sponsored coverage include Evenity on specialty tier (Tier 4 or 5) with prior authorization and step-therapy requirements. Typical step therapy mandates trial and failure of at least one oral bisphosphonate (alendronate or risedronate) before Evenity approval.

Horizon Blue Cross Blue Shield of New Jersey, the state's largest insurer, classifies Evenity under its specialty pharmacy program. Patient responsibility after PA approval ranges from $150 to $500 per injection depending on plan design and whether the medical or pharmacy benefit applies. UnitedHealthcare, Cigna, and Aetna plans sold in NJ follow similar patterns.

The distinction between medical benefit and pharmacy benefit matters significantly. When Evenity is administered in a physician's office, it typically bills under the medical benefit (J-code J3111), and the patient owes a percentage coinsurance rather than a flat copay. When dispensed through a specialty pharmacy for home administration, pharmacy benefit copay tiers apply. Patients should ask their insurer which pathway yields lower out-of-pocket cost.

The ARCH trial (N=4,093) demonstrated that romosozumab followed by alendronate reduced new vertebral fractures by 48% compared with alendronate alone at 24 months [2]. This clinical evidence strengthens PA appeals for patients with documented fracture history or very low bone density, as it establishes romosozumab as superior to the bisphosphonate that step-therapy protocols require first.

The Amgen/UCB Savings Card in New Jersey

Amgen's FIRST STEP program offers a copay savings card for commercially insured New Jersey patients. Eligible patients pay $0 out of pocket for each monthly injection, with Amgen covering up to $1,825 per dose. The card applies to the first 12 months of therapy.

Eligibility requirements are straightforward. Patients must carry commercial insurance (not Medicare, Medicaid, Tricare, or any government-funded program), have a valid prescription for Evenity, and reside in the United States. New Jersey has no state-level restrictions on manufacturer copay assistance programs, unlike some states that have enacted accumulator adjustment legislation affecting how copay cards interact with deductible and out-of-pocket maximum calculations.

However, patients should verify whether their specific plan uses a copay accumulator program. If it does, the savings card payments may not count toward the annual out-of-pocket maximum, potentially leaving the patient exposed to high costs after the card's benefit year expires. As of 2026, New Jersey has not passed legislation banning copay accumulators, though bills have been introduced in the state legislature.

To enroll, patients call 1-800-EVENITY or register through the Amgen patient support portal. The card is presented at the specialty pharmacy or physician's office at each administration visit.

Medicare Coverage for NJ Residents

Medicare Part B covers Evenity when administered in a physician's office as an "incident to" service, billing under J-code J3111. The standard Part B cost-sharing is 20% after the annual deductible ($257 in 2026), meaning Medicare beneficiaries owe approximately $365 per injection without supplemental coverage [3].

A Medigap plan (particularly Plan G or Plan N) can reduce or eliminate this 20% coinsurance. Medicare Advantage plans in New Jersey (Horizon Blue, UnitedHealthcare, Humana, Aetna) each set their own prior authorization criteria and cost-sharing structures for Part B drugs.

The Amgen FIRST STEP savings card explicitly excludes Medicare beneficiaries. However, Amgen's Evenity Patient Assistance Program (separate from the copay card) provides free medication to Medicare patients who meet income thresholds (generally below 300% of the federal poverty level). Applications require proof of income and a signed prescription.

Compounded Romosozumab Access in New Jersey

Licensed 503A compounding pharmacies in New Jersey can legally prepare romosozumab formulations pursuant to a valid patient-specific prescription. The New Jersey Board of Pharmacy regulates 503A facilities under N.J.A.C. 13:39, requiring them to compound in response to individual prescriptions rather than for bulk distribution [4].

A critical distinction: 503A compounded romosozumab is not an FDA-approved product. It does not undergo the same bioequivalence testing, stability studies, or batch-release testing as Amgen's branded Evenity. The FDA's guidance on compounding permits 503A pharmacies to compound copies of commercially available drugs only under specific conditions, and enforcement discretion has historically varied.

Patients considering compounded romosozumab should discuss with their prescriber the differences in quality assurance between an FDA-approved biologic and a pharmacy-compounded version. Romosozumab is a monoclonal antibody, and monoclonal antibody production typically requires mammalian cell culture systems that standard compounding pharmacies do not operate. Whether a 503A pharmacy can produce a true biosimilar-quality product is a matter of ongoing regulatory and scientific debate.

Cost for compounded versions, where legitimately available through a licensed 503A facility, may be substantially lower than brand Evenity, though patients should request certificates of analysis and verify the pharmacy's state inspection history through the NJ Board of Pharmacy's public database.

Telehealth Prescribing of Evenity in New Jersey

New Jersey permits telehealth prescribing of Evenity for osteoporosis management. The state's telehealth parity law (P.L. 2020, c.3) requires insurers to reimburse telehealth visits at the same rate as in-person encounters, and the prescriber-patient relationship can be established via a synchronous audio-video visit.

For Evenity specifically, the telehealth visit covers the prescribing decision, DXA interpretation, fracture risk assessment (FRAX score calculation), and PA documentation. The actual injection still requires an in-person visit at a clinic, infusion center, or home health setting. Some NJ-based telehealth osteoporosis practices coordinate both the virtual consultation and local injection scheduling.

This model works well for patients in underserved NJ counties (Salem, Cumberland, Cape May) where endocrinology or rheumatology access is limited. A telehealth specialist can manage the prescription and PA process while a local primary care office administers the injection.

Strategies to Reduce Evenity Cost in New Jersey

Several approaches can lower out-of-pocket costs for NJ residents beyond the manufacturer savings card.

Foundation assistance programs. The HealthWell Foundation and the National Osteoporosis Foundation's patient assistance fund offer copay support for commercially insured patients whose out-of-pocket costs exceed affordability thresholds. Income limits vary by program cycle and available funding.

Hospital outpatient 340B pricing. Patients treated at 340B-eligible institutions (many NJ hospital-affiliated clinics qualify) may benefit from lower acquisition costs that translate to reduced cost-sharing, particularly under medical benefit billing.

Specialty pharmacy shopping. While brand pricing is fixed, different specialty pharmacies apply different dispensing fees and may offer payment plans. Biologics by Mail, AllianceRx Walgreens, and Accredo all service NJ patients and each negotiates differently with payers.

Appeal step-therapy denials. For patients with very high fracture risk (prior vertebral fracture, T-score below -3.0, or glucocorticoid use), the American Association of Clinical Endocrinology guidelines support anabolic-first therapy without prior bisphosphonate trial. Citing AACE 2020 recommendations in a PA appeal can override step-therapy requirements.

Dr. Andrea Singer, Director of Women's Health at Georgetown, stated in the AACE guideline commentary: "For patients at very high fracture risk, beginning treatment with an osteoanabolic agent followed by an antiresorptive provides the greatest fracture risk reduction" [5]. This principle directly supports PA appeals for Evenity as first-line therapy in appropriate candidates.

Clinical Value Context for the Cost

The ARCH trial (N=4,093) compared romosozumab 210 mg monthly for 12 months followed by alendronate versus alendronate alone in postmenopausal women with osteoporosis and fragility fracture [2]. At 24 months, the romosozumab-to-alendronate sequence reduced new vertebral fractures by 48% (relative risk 0.52 to 95% CI 0.40 to 0.66, P<0.001) and clinical fractures by 27% compared with alendronate monotherapy.

The FRAME trial (N=7,180) showed romosozumab reduced new vertebral fractures by 73% versus placebo at 12 months (incidence 0.5% vs. 1.8%, P<0.001) [6]. Bone mineral density at the lumbar spine increased by 13.3% from baseline at month 12, the largest BMD gain demonstrated by any osteoporosis therapy in a phase 3 trial.

These efficacy data inform cost-effectiveness analyses. A 2021 ICER (Institute for Clinical and Economic Review) assessment estimated romosozumab's cost-effectiveness at approximately $150,000 per quality-adjusted life year (QALY) at list price, above the commonly cited $100,000-$150,000/QALY threshold but within range when accounting for fracture-related mortality reduction in very high-risk populations [7].

For a 70-year-old NJ woman with a prior vertebral fracture and T-score of -3.2, the number needed to treat (NNT) to prevent one vertebral fracture over 24 months (romosozumab then alendronate vs. alendronate alone) is approximately 14. At $21,900 per treated patient, the cost per fracture prevented is roughly $306,600, though this does not account for savings from avoided hospitalizations, which average $47,000 per hip fracture in the NJ/NY metro area.

Cardiovascular Safety Considerations Affecting Coverage

The FDA label for Evenity carries a boxed warning regarding potential increased risk of myocardial infarction, stroke, and cardiovascular death [1]. In the ARCH trial, cardiovascular serious adverse events occurred in 2.5% of romosozumab patients versus 1.9% of alendronate patients during the 12-month romosozumab treatment period.

This boxed warning directly affects insurance coverage in NJ. Most plans require prescribers to attest that the patient had no myocardial infarction or stroke within the preceding year, and some require documentation of cardiovascular risk assessment (Framingham or ASCVD risk score) as part of the PA process. Patients with a history of MI or stroke within 12 months are generally denied coverage per plan medical policy.

The Endocrine Society's position, published in the Journal of Clinical Endocrinology & Metabolism, recommends that "romosozumab should be avoided in patients at high cardiovascular risk" while noting that "the absolute cardiovascular risk increase observed in ARCH was small and the trial was not powered to assess CV outcomes" [8].